Core Viewpoint - Rosen Law Firm is reminding investors who purchased DoubleVerify Holdings, Inc. common stock during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought DoubleVerify common stock between November 10, 2023, and February 27, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by July 21, 2025 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in recovering significant amounts for investors [4]. - The firm has been recognized for its leadership in securities class action settlements, achieving the largest settlement against a Chinese company at the time and securing over $438 million for investors in 2019 alone [4]. Group 3: Allegations Against DoubleVerify - The lawsuit alleges that DoubleVerify made false and misleading statements regarding its business operations, including the shift of customer ad spending to closed platforms where its capabilities were limited [5]. - It is claimed that DoubleVerify's high-margin advertising optimization services faced significant challenges in monetization due to the high costs and time required for technology development on closed platforms [5]. - The lawsuit also points out that DoubleVerify overbilled customers for ad impressions served to bots and that its risk disclosures were misleading, leading to investor damages when the true situation was revealed [5].

NEW YORK, July 04, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) between June 22, 2023 and June 24, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 25, 2025. SO WHAT: If you purchased Sarepta securities during the ...

Meet America’s Best-In-State Lawyers 2025 https://t.co/MXwOhD7DLX #ForbesTopLawyers ...

Here’s How Sean ‘Diddy’ Combs’ Criminal Conviction Could Help Plaintiffs In His Dozens Of Civil Lawsuits https://t.co/Zfdp2vVs1p https://t.co/Zfdp2vVs1p ...

Who are the best lawyers in Minnesota? #ForbesTopLawyers https://t.co/dBgEMOIUvZ https://t.co/mTHeOgAvoX https://t.co/yiS6oz2irv ...

As we prepare to celebrate our country's 249th birthday, we are getting new insight into what Americans think about where the country stands. A new NPR PBS News mayor's poll found 34 of Americans feel that democracy is under serious threat and see politically motivated violence as a major problem. So, who better to talk about this moment in time than presidential historian John Meechum.He wrote a new introduction to Random Houses's volume of the Declaration of Independence and the Constitution. So, John, um ...

Indian stock traders will begin Friday digesting the news of Jane Street being temporarily barred over allegations of unlawful gains. Read for free with your email on what could move markets today https://t.co/9F2BjCxE4l ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased PepGen Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on August 8, 2025, for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought PepGen securities between March 7, 2024, and March 3, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by the deadline [2]. - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [3]. Group 2: Case Allegations - The lawsuit alleges that PepGen made false and misleading statements regarding the effectiveness and safety of PGN-EDO51, as well as the CONNECT2 study's suitability for FDA approval [4]. - It is claimed that due to these misrepresentations, PepGen was likely to halt the CONNECT2 study, leading to overstated clinical, regulatory, and commercial prospects for PGN-ED051 [4]. - The lawsuit asserts that when the true information became public, investors suffered damages as a result of the misleading statements [4]. Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong reputation in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time [3]. - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions for investors [3]. - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in litigation [3].

The Republican tax megabill is headed into law after passing the House. Here’s what it could mean for your finances. https://t.co/3QQkqv7ZlG ...

Here’s How Sean ‘Diddy’ Combs’ Criminal Conviction Could Help Plaintiffs In His Dozens Of Civil Lawsuits https://t.co/7ypJIGVLdq https://t.co/7ypJIGVLdq ...